A Phase 3, Open Label, Randomized Study Of LOXO-305 Versus Investigator’s Choice Of Idelalisib Plus Rituximab Or Bendamustine Plus Rituximab In Btk Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Email for information
Research Start Date
The primary objective of the study is to evaluate progression-free survival of LOXO-305 as monotherapy (Arm A) versus either idelalisib plus rituximab or bendamustine plus rituximab (Arm B).
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.